Could drugs inhibiting the mevalonate pathway also target cancer stem cells?

Understanding the connection between metabolic pathways and cancer is very important for the development of new therapeutic approaches based on regulatory enzymes in pathways associated with tumorigenesis. The mevalonate cascade and its rate-liming enzyme HMG CoA-reductase has recently drawn the attention of cancer researchers because strong evidences arising mostly from epidemiologic studies, show that it could promote transformation. Hence, these studies pinpoint HMG CoA-reductase as a candidate proto-oncogene.

Source: Drug Resistance Updates - February 20, 2016 Category: Drugs & Pharmacology Authors: Wirginia Likus, Krzysztof Siemianowicz, Konrad Bieńk, Małgorzata Pakuła, Himani Pathak, Chhanda Dutta, Qiong Wang, Shahla Shojaei, Yehuda G. Assaraf, Saeid Ghavami, Artur Cieślar-Pobuda, Marek J. Łos Source Type: research